Therapeutic for the Management of Pancreatic Head Adenocarcinoma about 40 Cases
Published: 2023-05-05
Page: 54-67
Issue: 2023 - Volume 6 [Issue 1]
Saad Rifki Jai
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Kenza Benjelloun Touimi *
Department of Digestive Cancer Surgery and Liver Transplantation, CHU Ibn Rochd, Casablanca, Morocco.
Amal Hajri
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Driss Erguibi
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Rachid Boufettal
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
Farid Chehab
Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Pancreatic cancer accounts for the majority of malignant pancreatic lesions. Its incidence is increasing and its prognosis is poor.
Most patients are asymptomatic during the early course of disease, which often leads to delay in diagnosis.
Treatment options include surgery, chemotherapy, and palliative care.
The objective of this work is to describe and analyze the epidemiological and clinical profile and the therapeutic management of adenocarcinomas of the head of the pancreas as well as to report the experience of the digestive oncology and liver transplant department of the CHU IBN ROCHD, through a retrospective study spread over a period of 02 years, from January 2020 to December 2022.
This work is important for scientific community because pancreatic cancers had remained without symptoms for a long time, and they are diagnosed at an advanced stage.
Keywords: Pancreas, adenocarcinoma, therapeutic